Give Now

Delays, Closings and Severe Weather - View All Alerts and Updates

Indiana Biotech Start-up Hoping For FDA Approval

An Indiana biotechnology start-up is hoping to get FDA approval to begin human testing on a new treatment for idiopathic pulmonary fibrosis, or IPF.

ImmuneWorks CEO Wade Lange says his company was founded on a discovery made by Chief Scientific Officer Dr. David Wilkes at the IU School of Medicine. He says Dr. Wilkes’ work revealed that the fatal lung disease is actually an auto-immune response to a form of collagen that is normally found in the lung.

Lange says if verified, that treatment model could be applied to other auto-immune diseases like lupus or rheumatoid arthritis. It was announced earlier this week that Indiana’s non-profit BioCrossroads seed fund has provided ImmuneWorks with a $300,000 investment. Lange says that investment will go a long way toward the production and safety testing the firm will have to take on before initiating clinical trials.

Want to contact your legislators about an issue that matters to you? Find out how to contact your senators and member of Congress here.

What is RSS? RSS makes it possible to subscribe to a website's updates instead of visiting it by delivering new posts to your RSS reader automatically. Choose to receive some or all of the updates from Indiana Public Media News:

Support For Indiana Public Media Comes From